Searchable abstracts of presentations at key conferences in endocrinology

ea0059ec2.2 | Navigating the academic | SFEBES2018

Early Careers: navigating the academic pathway. The clinical academic route

Salem Victoria

I will talk about my own experience pursuing a PhD, postdoctoral research and ultimately an Intermediate Clinician Scientist Fellowship alongside training in Diabetes and Endocrinology with GIM. I will talk about the particular barriers and challenges commonly reported by clinical academics and how universities and funding bodies are working to provide tailored support to help the furious juggle of research, grants, papers, on-calls, clinics and, yes, a home life....

ea0077oc2.3 | Endocrine Cancer and Late Effects | SFEBES2021

A novel in vivo platform for studying tumour vascularization and endocrine responses

Lopes Tatiana , Prague Julia , Salem Victoria , Owen Bryn

Background: Tumour growth is critically dependent on blood perfusion, its source of oxygen and nutrients. Therefore, tumour vascularization has become an attractive target for the treatment of many cancers types. The study of endocrine-responsive tumours, in particular, needs improved platforms to screen drugs targeting vascularization that have better resolution and that do not compromise on inter-individual variability.Aim: Hence, we’ve set out to...

ea0077p72 | Metabolism, Obesity and Diabetes | SFEBES2021

Impact of PCSK9 Inhibitors on hypercholesterolaemic patients at a tertiary centre lipid clinic

Israni Alisha , Jones Ben , Salem Victoria , Bravis Vassiliki

Background: Elevated low-density lipoprotein cholesterol (LDL-C), which arises due to genetic and environmental factors, has a causal role in the pathogenesis of cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are approved for patients with familial hypercholesterolaemia (FH) and patients at high risk of CVD due to non-familial hypercholesterolaemia (non-FH). In clinical trials, PCSK9 inhibitors are well-tolerated and lead to redu...

ea0050p015 | Adrenal and Steroids | SFEBES2017

How relevant is aldosterone and cortisol co-secretion?

Bhatt Padmanabh Shrikant , Sam Amir H , Salem Victoria , Meeran Karim

Background: Studies suggest that glucocorticoid hypersecretion alongside primary hyperaldosteronism (PA) is common and may contribute to the adverse metabolic phenotype. Adrenal crisis post-surgery for PA is rare.Aim: To determine the prevalence of cortisol co-secretion in PA in patients at Imperial College London NHS Trust, Hammersmith Hospital (a tertiary referral centre for adrenal tumours).Methods: Am...

ea0050p015 | Adrenal and Steroids | SFEBES2017

How relevant is aldosterone and cortisol co-secretion?

Bhatt Padmanabh Shrikant , Sam Amir H , Salem Victoria , Meeran Karim

Background: Studies suggest that glucocorticoid hypersecretion alongside primary hyperaldosteronism (PA) is common and may contribute to the adverse metabolic phenotype. Adrenal crisis post-surgery for PA is rare.Aim: To determine the prevalence of cortisol co-secretion in PA in patients at Imperial College London NHS Trust, Hammersmith Hospital (a tertiary referral centre for adrenal tumours).Methods: Am...

ea0044ep8 | (1) | SFEBES2016

Will the routine use of high dose steroids for alcoholic hepatitis result in an increased incidence of clinically significant hypocortisolism in patients with liver cirrhosis?

Karia Priya , Bravis Vassiliki , Salem Victoria , Radhakrishnan Shiva , Choa Dri

Introduction: Recent evidence supports the use of high dose steroids for 28 days in acute alcoholic hepatitis. We present a patient with Childs Pugh C liver cirrhosis, who developed adrenal axis suppression following such treatment. We discuss the complex aetiology and biochemistry of hypocortisolism in liver disease.Case: 48 year-old female admitted with alcoholic hepatitis, treated with a non-tapering 28-day course of 40 mg prednisolone. The patient wa...

ea0021p81 | Clinical practice/governance and case reports | SFEBES2009

Hypertension in familial adenomatous polyposis (FAP): don't be conn'd!

Hopkins Tom , Tan Tricia , Salem Victoria , Palazzo Fausto , Meeran Kareem

A 36-year-old man, presenting to his GP with severe intermittent headaches, was found to have a blood pressure of 210/110 mmHg. He had been diagnosed with familial adenomatous polyposis (FAP) in early childhood, and had had a total colectomy with ileo-rectal anastamosis at the age of 17. Routine surveillance CT imaging the following month revealed an incidental finding of bilateral adrenal masses (right 4×2 cm, left 2.7×2.9 cm).On assessment in...

ea0086p49 | Metabolism, Obesity and Diabetes | SFEBES2022

Investigating NtsR1-expressing neurons extending from the duodenum to pancreas

Meyer Leah , Norton Mariana , Rothery Stephen , Phuah Phyllis , Salem Victoria , Murphy Kevin

Neurotensin is widely expressed in the brain and gastrointestinal tract. Centrally, neurotensin acts as a neuropeptide to suppress appetite, induce hypothermia and modulate analgesia. Peripherally, neurotensin inhibits gastric emptying and is reported to aid lipid absorption. There is also evidence that neurotensin can influence glucose homeostasis, though this role is contentious. We have found that neurotensin acutely improves insulin release and glucose tolerance in mice, a...

ea0021p120 | Clinical practice/governance and case reports | SFEBES2009

The role of adrenal vein sampling (AVS) in the diagnosis and management of primary hyperaldosteronism: an audit of 10 years experience at a tertiary referral centre

Hopkins Tom , Salem Victoria , El-Gayar Heba , Tan Tricia , Palazzo Fausto , Meeran Kareem

Hyperaldosteronism is a significant cause of secondary hypertension, but there are often delays in obtaining the diagnosis. The recent BES publication of Guidelines for the investigation and management of this condition represent a move to standardise the work-up of these patients.We present an audit of cases, dating back to 2000, with confirmed biochemical hyperaldosteronism (on the basis of plasma aldosterone/renin activity ratio or lack of aldosterone...

ea0077ec1.4 | Clinical Endocrinology Trust Best Abstract Basic | SFEBES2021

The vagal Calcium Sensing Receptor mediates the effect of protein ingestion on insulin release and regulates macronutrient metabolism

Norton Mariana , Roberts Anna , Alonso Aldara Martin , Cao Ye , Gribble Fiona , Reimann Frank , Chang Wenhan , Salem Victoria , Murphy Kevin G

Protein stimulates insulin release and improves post-prandial glycaemic excursions. The underlying mechanism has previously been attributed to gastric emptying, incretin release and direct pancreatic stimulation. However, our studies suggest the calcium sensing receptor (CaSR) in the vagus nerve plays an important role. The CaSR has a well characterised role in calcium homeostasis, but also acts as a protein metabolite sensor. In response to the amino acid products of protein ...